1 – 1 of 1
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
(2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142
- Contribution to journal › Published meeting abstract